Deuremidevir
Clinical data
Trade names民得维
Routes of
administration		oral
Legal status
Legal status
  • US: Investigational drug
  • CN: conditially Rx
Identifiers
  • [(2R,3R,4R,5R)-5-(4-amino-5-deuteriopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC24H30DN5O7
Molar mass502.546 g·mol−1
3D model (JSmol)
  • [2H]c2cc([C@]1(C#N)O[C@H](COC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H]1OC(=O)C(C)C)n3ncnc(N)c23
  • InChI=InChI=1S/C24H31N5O7/c1-12(2)21(30)33-9-16-18(34-22(31)13(3)4)19(35-23(32)14(5)6)24(10-25,36-16)17-8-7-15-20(26)27-11-28-29(15)17/h7-8,11-14,16,18-19H,9H2,1-6H3,(H2,26,27,28)/t16-,18-,19-,24+/m1/s1/i7D
  • Key:RVSSLHFYCSUAHY-QXMJNOOVSA-N

Deuremidevir, also known as VV116, is an nucleoside analogue antiviral drug. It is administrated through oral tablets, which contain the hydrobromide salt of this drug.[1]

Chemically speaking, the drug is a deuterated tri-isobutyrate of GS-441524, the active metabolite of remdesivir. It was first described in an 2020 preprint by a team including members of Wuhan Institute of Virology and Vigonvita.[2] It completed a phase 3 trial in 2022.[3] Junshi, which markets the drug, received conditional approval from China's National Medical Products Administration in January 2023.[4]

In November 2023, in response to viral mutations and changing characteristics of infection, the WHO adjusted its treatment guidelines. Among other changes, the use of deuremidevir was recommended against, except for clinical trials.[5]

References

  1. ^ Zhu KW (September 2023). "Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19". ACS Pharmacology & Translational Science. 6 (9): 1306–1309. doi:10.1021/acsptsci.3c00134. PMC 10496140. PMID 37705591.
  2. ^ Yin W, Luan X, Li Z, Xie Y, Zhou Z, Liu J, Gao M, Wang X, Zhou F, Wang Q, Wang Q (January 2020). "Structural basis for repurpose and design of nucleoside drugs for treating COVID-19". bioRxiv. doi:10.1101/2020.11.01.363812. S2CID 226263471.
  3. ^ Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, et al. (February 2023). "VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19". The New England Journal of Medicine. 388 (5): 406–417. doi:10.1056/NEJMoa2208822. PMC 9812289. PMID 36577095.
  4. ^ Devarasetti H (2023-01-30). "China's NMPA conditionally approves two oral drugs for Covid-19". Pharmaceutical Technology. Retrieved 2023-02-04.
  5. ^ "WHO updates its guidance on treatments for COVID-19". BMJ (Press release). 9 November 2023.
Categories